JP2024515770A - タファミジスの固体形態及びその製造方法 - Google Patents

タファミジスの固体形態及びその製造方法 Download PDF

Info

Publication number
JP2024515770A
JP2024515770A JP2023565586A JP2023565586A JP2024515770A JP 2024515770 A JP2024515770 A JP 2024515770A JP 2023565586 A JP2023565586 A JP 2023565586A JP 2023565586 A JP2023565586 A JP 2023565586A JP 2024515770 A JP2024515770 A JP 2024515770A
Authority
JP
Japan
Prior art keywords
benzoxazole
dichlorophenyl
carboxylic acid
crystalline form
tafamidis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515770A5 (https=
Inventor
バッレーカ，ジュゼッペ
カーコーネ，ルカ
パラヴィディーノ，ピエロ
ペンゴ，ダニエル
ザンピエーリ，マッシモ
フアン，リミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quimica Sintetica SA
Original Assignee
Quimica Sintetica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quimica Sintetica SA filed Critical Quimica Sintetica SA
Publication of JP2024515770A publication Critical patent/JP2024515770A/ja
Publication of JP2024515770A5 publication Critical patent/JP2024515770A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
JP2023565586A 2021-04-26 2022-04-22 タファミジスの固体形態及びその製造方法 Pending JP2024515770A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382362.8 2021-04-26
EP21382362.8A EP4083027A1 (en) 2021-04-26 2021-04-26 A solid state form of tafamidis and a process for its preparation
PCT/EP2022/060716 WO2022229026A1 (en) 2021-04-26 2022-04-22 A solid state form of tafamidis and a process for its preparation

Publications (2)

Publication Number Publication Date
JP2024515770A true JP2024515770A (ja) 2024-04-10
JP2024515770A5 JP2024515770A5 (https=) 2025-03-10

Family

ID=75746555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565586A Pending JP2024515770A (ja) 2021-04-26 2022-04-22 タファミジスの固体形態及びその製造方法

Country Status (8)

Country Link
US (1) US20240208915A1 (https=)
EP (2) EP4083027A1 (https=)
JP (1) JP2024515770A (https=)
CN (1) CN117255781A (https=)
BR (1) BR112023022116A2 (https=)
CA (1) CA3216325A1 (https=)
MX (1) MX2023012460A (https=)
WO (1) WO2022229026A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250042864A1 (en) * 2021-11-17 2025-02-06 Teva Pharmaceuticals International Gmbh Solid state form of tafamidis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016065042A (ja) * 2014-09-08 2016-04-28 ファイザー・インク ６−カルボキシ−２−（３，５−ジクロロフェニル）−ベンゾオキサゾールの結晶性固体形態
WO2020232325A1 (en) * 2019-05-16 2020-11-19 Teva Pharmaceuticals International Gmbh Solid state forms of tafamidis and salts thereof
WO2021001858A1 (en) * 2019-07-04 2021-01-07 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2800237C (en) 2002-12-19 2016-05-17 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
RU2565066C2 (ru) * 2010-04-21 2015-10-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные 1-(2-фторбифенил-4-ил)-алкилкарбоновой кислоты для лечения транстиретинового амилоидоза
RU2586330C2 (ru) 2011-09-16 2016-06-10 Пфайзер Инк. Твердые формы ингибитора диссоциации транстиретина
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
WO2021019448A1 (en) 2019-08-01 2021-02-04 Honour (R&D) Process for the preparation of transthyretin dissociation inhibitor
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
US12522573B2 (en) * 2020-10-19 2026-01-13 Alivus Life Sciences Limited Process for preparation of tafamidis and salts thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016065042A (ja) * 2014-09-08 2016-04-28 ファイザー・インク ６−カルボキシ−２−（３，５−ジクロロフェニル）−ベンゾオキサゾールの結晶性固体形態
WO2020232325A1 (en) * 2019-05-16 2020-11-19 Teva Pharmaceuticals International Gmbh Solid state forms of tafamidis and salts thereof
WO2021001858A1 (en) * 2019-07-04 2021-01-07 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
小嶌隆史: "医薬品開発における結晶性選択の効率化を目指して", 薬剤学, vol. 68, no. 5, JPN6009053757, 1 September 2008 (2008-09-01), pages 344 - 349, ISSN: 0005728560 *
浅原 照三, 溶剤ハンドブック, JPN6011026738, 1985, pages 47 - 51, ISSN: 0005728564 *
社団法人日本化学会, 化学便覧応用化学編第６版, vol. 第4章化学合成技術, JPN6009048258, 30 January 2003 (2003-01-30), pages 178, ISSN: 0005728562 *
芦澤一英, 医薬品の多形現象と晶析の科学, JPN6018028449, 2002, pages 56 - 102, ISSN: 0005728561 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005728563 *

Also Published As

Publication number Publication date
US20240208915A1 (en) 2024-06-27
WO2022229026A1 (en) 2022-11-03
BR112023022116A2 (pt) 2024-01-09
EP4083027A1 (en) 2022-11-02
CN117255781A (zh) 2023-12-19
EP4330237A1 (en) 2024-03-06
MX2023012460A (es) 2023-12-14
CA3216325A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
JP7444957B2 (ja) ２－ヒドロキシ－６－（（２－（１－イソプロピル－１ｈ－ピラゾール－５－イル）ピリジン－３－イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形
CN110494423B (zh) 乐伐替尼甲磺酸盐的新晶型及其制备方法
WO2023078424A1 (zh) Kras突变体抑制剂的晶型、其制备方法及其应用
US10689380B1 (en) Crystalline forms of valbenazine ditosylate
US9809551B2 (en) Solid forms of Ivacaftor and processes for the preparation thereof
HUE026408T2 (en) Dabigatran etexylate bis-mesylate salt, solid forms and process for their preparation
US20090076272A1 (en) Polymorphs of eszopiclone malate
CN110903239A (zh) 乐伐替尼甲磺酸盐的新晶型及其制备方法
JP2024515770A (ja) タファミジスの固体形態及びその製造方法
US11236073B2 (en) ODM-201 crystalline form, preparation method therefor, and pharmaceutical composition thereof
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
JP5847567B2 (ja) 活性医薬成分の結晶形態
WO2018233678A1 (zh) 右旋雷贝拉唑钠化合物及其药物组合物
US11214547B2 (en) Crystalline Eltrombopag monoethanolamine salt form D
TWI324517B (en) 4-(4-trans-hydroxycyclohexyl)amino-2-phenyl-7h-pyrrolo[2,3d]pyrimidine hydrogen mesylate and its polymorphic forms
US10995083B2 (en) Cocrystal of 2-(6-methyl-pyridine-2-yl)-3-yl-[6-amide-quinoline-4-yl]-5,6-dihydro-4H-pyrrole[1,2-b]pyrazole, preparation method therefor, and pharmaceutical composition
US20240270733A1 (en) Hydrate form of lazertinib mesylate, preparation method thereof and use thereof
US20200283381A1 (en) Solid state forms of elafibranor
US12528795B2 (en) Crystal form of multi-substituted benzene ring compound maleate, and preparation method therefor and use thereof
US20240327379A1 (en) Mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one
EP3412661A1 (en) Cocrystals of vortioxetine hydrobromide and resorcinol
US20230064976A1 (en) Amorphous form or crystalline form of 2-indolinolinololylspironone compounds or their salts, solvent complexes
JP2025525196A (ja) （Ｓ）－７－オキサ－２－アザ－スピロ［４．５］デカン－２－カルボン酸［７－（３，６－ジヒドロ－２Ｈ－ピラン－４－イル）－４－メトキシ－チアゾロ［４，５－ｃ］ピリジン－２－イル］－アミドの新規結晶形態およびその共結晶形態
EP3075724B1 (en) Solid form of agomelatine
WO2024023796A1 (en) Polymorphs, co-crystals and solvates of fruquintinib, processes for the preparation and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260410